The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia

Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties

Travis T. Wager, Xinjun Hou, Patrick R. Verhoest et al. · ACS Chemical Neuroscience · 2010 · 1K citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

C J Schmidt, Douglas S. Chapin, J. Cianfrogna et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 284 citations

Medicine, Neuroscience, Pharmacology +13

Cassette‐accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery

Walter A. Korfmacher, Kathleen Cox, Kwokei Ng et al. · Rapid Communications in Mass Spectrometry · 2001 · 151 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Use of Structure-Based Design to Discover a Potent, Selective, In Vivo Active Phosphodiesterase 10A Inhibitor Lead Series for the Treatment of Schizophrenia

Christopher J. Helal, Zhijun Kang, Xinjun Hou et al. · Journal of Medicinal Chemistry · 2011 · 52 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Characterization of the selective mGluR1 antagonist, JNJ16259685, in rodent models of movement and coordination

Robert A. Hodgson, Lynn A. Hyde, Donald H. Guthrie et al. · Pharmacology Biochemistry and Behavior · 2010 · 15 citations

Life Sciences, Neuroscience, Pharmacology +12